| Dr Richard Key, MD | |
|
8227 Reseda Boulevard, Northridge Diagnostic Center, Northridge, CA 91335-0000 | |
| (818) 773-6500 | |
| (818) 701-5936 |
| Full Name | Dr Richard Key |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 8227 Reseda Boulevard, Northridge, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801916499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | G37219 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard Key, MD 1516 Cotner Ave, Los Angeles, CA 90025-3303 Ph: (310) 445-2951 | Dr Richard Key, MD 8227 Reseda Boulevard, Northridge Diagnostic Center, Northridge, CA 91335-0000 Ph: (818) 773-6500 |
News Archive
Low dose aspirin is recommended by clinicians as a preventive measure for patients who have already had a heart attack or stroke, but the risk of taking low-dose aspirin to prevent or delay a first heart attack or stroke is less clear, as the benefit for reducing the risk of cardiovascular disease (CVD) must be balanced with the increased risk of gastrointestinal or other bleeding.
Cancer Council Queensland has welcomed recommended changes to Australia's cervical screening program announced today by Australia's Medical Services Advisory Committee.
Spanish researchers have demonstrated that the relationship between marathon running times and the age of the athlete is U-shaped. The work shows the unusual fact that it takes an 18-year-old athlete the same amount of time to finish a marathon as a 55- or 60-year-old runner.
The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc., received U.S. Food and Drug Administration (FDA) approval for Kyprolis (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy.
› Verified 5 days ago
Matthew P Beatty, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 18300 Roscoe Blvd, Northridge, CA 91328 Phone: 818-885-8500 | |
Steven L Cole, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 18300 Roscoe Blvd, Northridge, CA 91328 Phone: 818-885-8500 | |
Ivan C Rokos, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 18300 Roscoe Blvd, Northridge, CA 91328 Phone: 818-885-8500 | |
Boris Viadamir Lubavin, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 8510 Balboa Blvd, Ste 150, Northridge, CA 91325 Phone: 888-988-2800 | |
Gabriel Henry Campion, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 18300 Roscoe Blvd, Northridge, CA 91325 Phone: 818-885-8500 | |
Shannon M Mcfarland, PA Emergency Medicine Medicare: Medicare Enrolled Practice Location: 18300 Roscoe Blvd, Northridge, CA 91328 Phone: 818-885-8500 | |
Alfred M Pascual, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 18300 Roscoe Blvd, Northridge, CA 91328 Phone: 818-885-8500 |